MTOR and hepatocellular carcinoma: In a phase 1b clinical trial of RO4929097 combined with temsirolimus, an inhibitor of mTOR, in patients with advanced solid tumors, including patients with advanced HCC, RO4929097 was considered safe when combined with temsirolimus.